{"id":745693,"date":"2018-07-24T05:45:00","date_gmt":"2018-07-24T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/"},"modified":"2025-11-07T01:27:10","modified_gmt":"2025-11-07T06:27:10","slug":"merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/","title":{"rendered":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical<br \/>\n      trial evaluating the efficacy and safety of doravirine (DOR), the<br \/>\n      company\u2019s investigational non-nucleoside reverse transcriptase inhibitor<br \/>\n      (NNRTI), in combination with other antiretroviral agents, for the<br \/>\n      treatment of HIV-1 infection in adult patients with no prior<br \/>\n      antiretroviral treatment history (treatment-na\u00efve). At Week 96, 73.1<br \/>\n      percent (277\/379) of the group treated with once-daily DOR achieved<br \/>\n      viral suppression as measured by the proportion of patients who achieved<br \/>\n      HIV-1 RNA of less than 50 copies\/mL, compared to 66.0 percent (248\/376)<br \/>\n      of the group treated with once-daily ritonavir-boosted darunavir (DRV+r)<br \/>\n      (treatment difference: 7.1%, 95% confidence interval: 0.5, 13.7). These<br \/>\n      study results were presented today as a late-breaking abstract at the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aids2018.org%2F&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=22nd+International+AIDS+Conference&amp;index=1&amp;md5=d2ae8562c598dd1ce659e70ab866dfa9\" rel=\"nofollow\">22<sup>nd<\/sup><br \/>\n      International AIDS Conference<\/a> (AIDS 2018) taking place July 23-27,<br \/>\n      2018, in Amsterdam.\n    <\/p>\n<p>\n      Previously, the findings at Week 48 demonstrated that once-daily DOR met<br \/>\n      its primary efficacy endpoint of non-inferiority compared to DRV+r, each<br \/>\n      in combination with emtricitabine\/tenofovir disoproxil fumarate<br \/>\n      (FTC\/TDF) or abacavir\/lamivudine (ABC\/3TC). These data were presented at<br \/>\n      the Conference on Retroviruses and Opportunistic Infections in 2017.\n    <\/p>\n<p>\n      \u201cThese Week 96 data reinforce the efficacy and safety of doravirine<br \/>\n      found at 48 weeks, and support the potential use of doravirine in the<br \/>\n      clinic as an important new treatment option for people living with<br \/>\n      HIV-1,\u201d said Professor Chloe Orkin, lead for HIV and HIV\/Hep C research,<br \/>\n      Ambrose King Centre, Royal London Hospital.\n    <\/p>\n<p>\n      <b>Data from DRIVE-FORWARD<\/b><br \/>\n<br \/>In DRIVE-FORWARD, 766 participants<br \/>\n      (n=383 in each treatment group) with no antiretroviral treatment history<br \/>\n      were randomized and received either DOR (100 mg) once daily or DRV+r<br \/>\n      (800 mg and 100 mg, respectively) once daily, each in combination with<br \/>\n      FTC\/TDF or ABC\/3TC selected by the investigator. In this trial, after 96<br \/>\n      weeks of treatment, the proportion of participants achieving HIV-1 RNA<br \/>\n      less than 50 copies\/mL was 73.1 percent (277\/379) in the DOR group and<br \/>\n      66.0 percent (248\/376) in the DRV+r group (treatment difference: 7.1%,<br \/>\n      95% confidence interval: 0.5, 13.7). Results for participants with high<br \/>\n      baseline viral load (HIV-1 RNA greater than 100,000 copies\/mL) were 65.4<br \/>\n      percent (51\/78) for DOR and 65.2 percent (43\/66) for DRV+r (treatment<br \/>\n      difference: -1.1%, 95% confidence interval: -17.6, 15.3). In addition,<br \/>\n      the mean change from baseline in CD4+ T-cell count at 96 weeks was 224<br \/>\n      cells\/mm<sup>3<\/sup> for DOR and 207 cells\/mm<sup>3<\/sup> for DRV+r<br \/>\n      (treatment difference: 17.4 cells\/mm<sup>3<\/sup>, 95% confidence<br \/>\n      interval: -14.5, 49.3). In terms of resistance, two participants in the<br \/>\n      DOR treatment group (15 with successful genotype test) developed<br \/>\n      genotypic and phenotypic resistance to DOR through 96 weeks of treatment.\n    <\/p>\n<p>\n      The most common adverse events occurring in greater than or equal to 10<br \/>\n      percent of participants in either treatment group through 96 weeks were<br \/>\n      diarrhea (DOR 17.0% [65\/383], DRV+r 23.8% [91\/383]), nausea (DOR 11.7%<br \/>\n      [45\/383], DRV+r 13.6% [52\/383]), headache (DOR 14.9% [57\/383], DRV+r<br \/>\n      12.0% [46\/383]), upper respiratory tract infection (DOR 13.3% [51\/383],<br \/>\n      DRV+r 7.8% [30\/383]), and viral upper respiratory tract infection (DOR<br \/>\n      11.5% [44\/383] and DRV+r 13.1% [50\/383]). The rate of discontinuation of<br \/>\n      therapy due to adverse events was 1.6 percent (6\/383) in the DOR group<br \/>\n      and 3.4 percent (13\/383) in the DRV+r group.\n    <\/p>\n<p>\n      At Week 96 mean changes from baseline in fasting serum blood lipids for<br \/>\n      the DOR and DRV+r treated groups in levels of low density lipoprotein<br \/>\n      cholesterol (LDL-C) were DOR -0.4 mg\/dL and DRV+r 14.0 mg\/dL (treatment<br \/>\n      difference: -14.6, 95% confidence interval: -18.2, -11.0)<b>;<\/b> and in<br \/>\n      levels of non-high density lipoprotein cholesterol (non-HDL-C) were DOR<br \/>\n      -0.5 mg\/dL and DRV+r 17.7 mg\/dL (treatment difference: -18.4, 95%<br \/>\n      confidence interval: -22.5, -14.3). Mean changes from baseline in total<br \/>\n      cholesterol, high density lipoprotein cholesterol (HDL-C), and<br \/>\n      triglycerides for the DOR-treated group and the DRV+r treated group were<br \/>\n      4.1 mg\/dL and 21.9 mg\/dL (treatment difference: -18.1, 95% confidence<br \/>\n      interval: -22.5, -13.7), 4.5 mg\/dL and 4.2 mg\/dL (treatment difference:<br \/>\n      0.4, 95% confidence interval: -1.3, 2.1), and -1.1 mg\/dL and 22.5 mg\/dL<br \/>\n      (treatment difference: -25.7, 95% confidence interval: -36.6, -14.7),<br \/>\n      respectively.\n    <\/p>\n<p>\n      \u201cFor more than 30 years, Merck has advanced innovative science to help<br \/>\n      change the trajectory in how HIV is treated. Today, our work is focused<br \/>\n      on clinical research that is designed to truly address unmet patient<br \/>\n      need,\u201d said George Hanna, MD, vice president and therapeutic area head<br \/>\n      of infectious diseases, global clinical development, Merck Research<br \/>\n      Laboratories. \u201cWe are encouraged by the 96 Week results of the<br \/>\n      DRIVE-FORWARD trial which support the efficacy and durability of<br \/>\n      investigational NNRTI doravirine.\u201d\n    <\/p>\n<p>\n      <b>About DRIVE-FORWARD<\/b><br \/>\n<br \/>DRIVE-FORWARD is a multicenter,<br \/>\n      double-blind, randomized non-inferiority trial in which 766<br \/>\n      treatment-na\u00efve adults with HIV-1 infection received either 100 mg<br \/>\n      doravirine or 800 mg darunavir plus 100 mg ritonavir, both administered<br \/>\n      orally once-daily in combination with either FTC\/TDF or ABC\/3TC. The<br \/>\n      primary endpoint of the clinical trial was the proportion of<br \/>\n      participants with HIV-1 RNA copies of less than 50 copies\/mL at Week 48.<br \/>\n      There were a number of secondary endpoints, including efficacy at Week<br \/>\n      96, an evaluation of the effects of DOR and DRV+r on fasting serum<br \/>\n      lipids, change from baseline in CD4+ T-cell count, and evaluation of<br \/>\n      safety and tolerability. For further information regarding DRIVE-FORWARD<br \/>\n      please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=a16da79eae974705fab9b54bb3c8bede\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n      clinical trial registry number NCT02275780.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b><br \/>\n<br \/>Doravirine (DOR) is an investigational<br \/>\n      NNRTI being evaluated by Merck for the treatment of HIV-1 infection. DOR<br \/>\n      is being evaluated in several ongoing clinical trials both as a<br \/>\n      once-daily single-entity tablet in combination with other antiretroviral<br \/>\n      agents in a tailored regimen, and as a once-daily fixed-dose combination<br \/>\n      (DOR\/3TC\/TDF) in a complete single tablet regimen. Phase 3 trials<br \/>\n      include DRIVE-FORWARD, a trial comparing DOR to once-daily<br \/>\n      ritonavir-boosted darunavir (DRV+r), each administered in combination<br \/>\n      with FTC\/TDF or ABC\/3TC, in treatment-na\u00efve adults; DRIVE-AHEAD, a trial<br \/>\n      comparing DOR\/3TC\/TDF to efavirenz (EFV)\/FTC\/TDF in treatment-na\u00efve<br \/>\n      adults; and DRIVE-SHIFT, a trial evaluating a switch to DOR\/3TC\/TDF in<br \/>\n      HIV-1 infected adults who are currently virologically suppressed on<br \/>\n      another antiretroviral regimen. Other ongoing Phase 2 clinical trials<br \/>\n      include an evaluation of DOR\/3TC\/TDF in treatment-na\u00efve adults with<br \/>\n      transmitted resistance to NNRTIs and in people switching from EFV due to<br \/>\n      intolerability.\n    <\/p>\n<p>\n      Earlier this year, the U.S. Food and Drug Administration (FDA) accepted<br \/>\n      for review New Drug Applications for DOR and DOR\/3TC\/TDF for the<br \/>\n      treatment of HIV-1 infection in treatment-na\u00efve adults. The FDA has set<br \/>\n      a target action date of October 23, 2018 for both applications.\n    <\/p>\n<p>\n      <b>Our Commitment to HIV<\/b><br \/>\n<br \/>For more than 30 years, Merck has been<br \/>\n      committed to scientific research and discovery in HIV and we continue to<br \/>\n      be driven by the conviction that more medical advances are still to<br \/>\n      come. Our focus is on pursuing research that addresses unmet medical<br \/>\n      needs and helps people living with HIV and their communities. We are<br \/>\n      making choices, including in our HIV pipeline, that could potentially<br \/>\n      change the HIV treatment and prevention paradigms, and help bring us<br \/>\n      closer to the goal of finding a cure. We remain committed to working<br \/>\n      hand-in-hand with our partners in the global HIV community to address<br \/>\n      the complex challenges to continued progress.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world&#8217;s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer&#8217;s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=6ebee26fbc084a0cff33eeaa7bfba6d1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=2b816b165499933121dec68dfcf265d0\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=ef9b848a996b65c225587652e80e93b2\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=d498bc3fa07fca68af0b473a8c6c7020\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=e87522d56ea9e842bc4e3fb2d36aff27\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=5bb493d4fdf1e8604f3bbfb2cc80b1d1\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51841518&amp;newsitemid=20180724005161&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=c95439151acfacd10174900fefaa3963\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180724005161r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Carmen de        Gourville, 267-305-4195<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history (treatment-na\u00efve). At Week 96, 73.1 percent (277\/379) of the group treated with once-daily DOR achieved viral suppression as measured by the proportion of patients who achieved HIV-1 RNA of less than 50 copies\/mL, compared to 66.0 percent (248\/376) of the group treated with once-daily ritonavir-boosted darunavir (DRV+r) (treatment difference: 7.1%, 95% confidence interval: 0.5, 13.7). These study results were presented today as a late-breaking abstract at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27, 2018, in Amsterdam.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745693","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history (treatment-na\u00efve). At Week 96, 73.1 percent (277\/379) of the group treated with once-daily DOR achieved viral suppression as measured by the proportion of patients who achieved HIV-1 RNA of less than 50 copies\/mL, compared to 66.0 percent (248\/376) of the group treated with once-daily ritonavir-boosted darunavir (DRV+r) (treatment difference: 7.1%, 95% confidence interval: 0.5, 13.7). These study results were presented today as a late-breaking abstract at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27, 2018, in Amsterdam.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\\\/\",\"name\":\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-07-24T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the company\u2019s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history (treatment-na\u00efve). At Week 96, 73.1 percent (277\/379) of the group treated with once-daily DOR achieved viral suppression as measured by the proportion of patients who achieved HIV-1 RNA of less than 50 copies\/mL, compared to 66.0 percent (248\/376) of the group treated with once-daily ritonavir-boosted darunavir (DRV+r) (treatment difference: 7.1%, 95% confidence interval: 0.5, 13.7). These study results were presented today as a late-breaking abstract at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27, 2018, in Amsterdam.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:10+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/","name":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-07-24T05:45:00+00:00","dateModified":"2025-11-07T06:27:10+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7cc6f66d-7444-4892-b449-b7fe35c2daec","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745693\/revisions"}],"predecessor-version":[{"id":3675036,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745693\/revisions\/3675036"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745693"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}